Clearside Biomedical, Inc. announced that it will conduct a randomized, controlled, double-masked, Phase 2b clinical trial, called ODYSSEY, in wet AMD participants. Based on the draft guidance on wet AMD drug development released on February 24, 2023, by the U.S. Food & Drug Administration (FDA), plan to adjust trial design to use on-label aflibercept dosing in the comparator arm of ODYSSEY. The company expects a seamless transition to this adjusted trial design and plan to open trial enrollment in the second quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.27 USD | +3.25% |
|
-0.78% | +8.55% |
Jun. 25 | Oppenheimer Initiates Clearside Biomedical at Outperform With $5 Price Target | MT |
May. 13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.55% | 94.91M | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Announces Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Second Quarter of 2023